statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management Flagship Pioneering and Metaphore...

Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates. 'With a broad indication and...

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading microbiome therapeutics company, today announced that on May 1, 2024, the Compensation and Talent Committee of Seres board of...

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET...

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in...

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences PR Newswire...

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres board...

Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative...

Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024

Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading microbiome therapeutics company, today announced that on March 13, 2024, the Compensation and Talent Committee of Seres board...

Key Insights Given the large stake in the stock by institutions, Seres Therapeutics' stock price might be vulnerable to...

Institutional owners may take dramatic actions as Seres Therapeutics, Inc.'s (NASDAQ:MCRB) recent 25% drop adds to one-year losses

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Watchers	9,218
52-Wk Low	$0.54
52-Wk High	$6.26

Volume	8,341.00
52-Wk High	$6.26
52-Wk Low	$0.54

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.29	--	--	N/A
Q1'24	-$0.34	-$0.27	20.98%	BEAT
Q4'23	-$0.39	-$0.31	20.83%	BEAT
Q3'23	-$0.50	-$0.37	26.21%	BEAT
Q2'23	$0.53	$0.36	-32.64%	MISSED

MCRB Seres Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals